BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 28984195)

  • 1. MD-Miner: a network-based approach for personalized drug repositioning.
    Wu H; Miller E; Wijegunawardana D; Regan K; Payne PRO; Li F
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):86. PubMed ID: 28984195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel individualized drug repositioning approach for predicting personalized candidate drugs for type 1 diabetes mellitus.
    Zheng H
    Stat Appl Genet Mol Biol; 2019 Jul; 18(5):. PubMed ID: 31287801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks.
    Liu H; Song Y; Guan J; Luo L; Zhuang Z
    BMC Bioinformatics; 2016 Dec; 17(Suppl 17):539. PubMed ID: 28155639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Drug Repositioning with Random Walk on a Heterogeneous Network.
    Luo H; Wang J; Li M; Luo J; Ni P; Zhao K; Wu FX; Pan Y
    IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(6):1890-1900. PubMed ID: 29994051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease.
    Zhao M; Yang CC
    J Med Internet Res; 2018 Oct; 20(10):e271. PubMed ID: 30309833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.
    Xu J; Regan-Fendt K; Deng S; Carson WE; Payne PRO; Li F
    Pac Symp Biocomput; 2018; 23():92-103. PubMed ID: 29218872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer.
    Chen HR; Sherr DH; Hu Z; DeLisi C
    BMC Med Genomics; 2016 Jul; 9(1):51. PubMed ID: 27475327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational drug repositioning using meta-path-based semantic network analysis.
    Tian Z; Teng Z; Cheng S; Guo M
    BMC Syst Biol; 2018 Dec; 12(Suppl 9):134. PubMed ID: 30598084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network.
    Jadamba E; Shin M
    Biomed Res Int; 2016; 2016():7147039. PubMed ID: 28127549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DrugNet: network-based drug-disease prioritization by integrating heterogeneous data.
    Martínez V; Navarro C; Cano C; Fajardo W; Blanco A
    Artif Intell Med; 2015 Jan; 63(1):41-9. PubMed ID: 25704113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network-Based Drug Repositioning: Approaches, Resources, and Research Directions.
    Alaimo S; Pulvirenti A
    Methods Mol Biol; 2019; 1903():97-113. PubMed ID: 30547438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mining heterogeneous network for drug repositioning using phenotypic information extracted from social media and pharmaceutical databases.
    Yang CC; Zhao M
    Artif Intell Med; 2019 May; 96():80-92. PubMed ID: 31164213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles.
    Wang L; Li F; Sheng J; Wong ST
    BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S6. PubMed ID: 26099165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
    Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-resolved evaluation of compound repositioning predictions on a text-mined knowledge network.
    Mayers M; Li TS; Queralt-Rosinach N; Su AI
    BMC Bioinformatics; 2019 Dec; 20(1):653. PubMed ID: 31829175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
    Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
    Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network mirroring for drug repositioning.
    Park S; Lee DG; Shin H
    BMC Med Inform Decis Mak; 2017 May; 17(Suppl 1):55. PubMed ID: 28539121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DrPOCS: Drug Repositioning Based on Projection Onto Convex Sets.
    Wang YY; Cui C; Qi L; Yan H; Zhao XM
    IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(1):154-162. PubMed ID: 29993698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma.
    Zhu FX; He YC; Zhang JY; Wang HF; Zhong C; Wang XT
    Med Sci Monit; 2019 May; 25():3247-3255. PubMed ID: 31048671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug repositioning using drug-disease vectors based on an integrated network.
    Lee T; Yoon Y
    BMC Bioinformatics; 2018 Nov; 19(1):446. PubMed ID: 30463505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.